Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile
- Lexeo Therapeutics Reports Decreased Losses and Strong Cash Position
- Lexeo Therapeutics files to sell 1.25M shares of common stock for holders
- Lexeo Therapeutics reports Q3 EPS (33c), consensus (44c)
- Lexeo Therapeutics selloff looks ‘highly unwarranted,’ says H.C. Wainwright